Celularity Inc. (CELU) Income Statement
CELU 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCELU revenue and net income
Where CELU's revenue goes
2025Each bar shows an amount and its share of revenue. CELU kept −345.8% of revenue as net income.
CELU profit margins
CELU growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −51.0% | +13.9% | +13.2% | — |
| Gross profit | −48.5% | — | +16.7% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CELU quarterly EPS vs estimates
Celularity beat the analyst EPS estimate in 2 of the last 4 quarters. Next report: November 13, 2026.
CELU income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M | $14.3M | $21.1M | $17.6M |
| Cost of revenue | $6.4M | $15.0M | $16.0M | $19.7M | $9.7M | $4.9M | $6.3M | $6.6M |
| Gross profit | $20.2M | $39.2M | $6.8M | −$1.7M | $11.7M | $9.3M | $14.8M | $11.0M |
| Research & development | $15.0M | $17.4M | $30.5M | $78.4M | $88.4M | $52.7M | $46.1M | $29.1M |
| Sales, general & admin | $51.3M | $58.6M | $50.6M | $65.9M | $71.1M | $31.3M | $41.8M | — |
| Total operating expenses | $81.5M | $77.6M | $99.2M | $23.9M | $120.7M | $161.3M | $279.0M | $1,098 |
| Operating income | −$61.3M | −$38.4M | −$76.5M | −$25.6M | −$109.1M | −$151.9M | −$264.1M | −$1,098 |
| Interest income | $262,000 | $331,000 | $320,000 | $365,000 | $332,000 | $370,000 | — | — |
| Interest expense | $6.8M | $6.3M | $3.0M | $3.2M | $3.2M | $2.4M | $3.7M | $0 |
| Income before taxes | −$91.7M | −$57.9M | −$196.3M | $14.2M | −$100.1M | −$212.9M | −$268.0M | −$1,098 |
| Income taxes | $3,000 | $10,000 | — | $13,000 | $20,000 | −$4.7M | −$56.1M | $21.3M |
| Net income | −$91.8M | −$57.9M | −$196.3M | $14.2M | −$100.1M | −$208.2M | −$211.9M | −$1,098 |
| EBITDA | −$77.7M | −$43.7M | −$183.9M | −$138.8M | −$88.1M | −$202.4M | −$71.0M | −$1,098 |
| EPS (diluted) | −$3.18 | −$2.65 | −$7.80 | −$4.43 | $3.76 | −$0.03 | $0.26 | $0.00 |
| Gross margin | 76.0% | 72.4% | 29.7% | −9.4% | 54.8% | 65.5% | 70.1% | 62.7% |
| Operating margin | −230.9% | −70.7% | −335.9% | −142.4% | −511.2% | −1,064.0% | −1,249.0% | −0.0% |
| Net margin | −345.8% | −106.8% | −862.0% | 79.0% | −469.3% | −1,458.4% | −1,001.9% | −0.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $4.1M | $4.1M | $5.3M | $5.7M | $18.1M | $18.1M | $9.3M | $12.1M | $14.7M | $3.8M | $3.8M |
| Cost of revenue | $1.1M | −$4.5M | $7.4M | $2.0M | $5.2M | $7.3M | $7.3M | $3.9M | $9.6M | $1.6M | $3.6M | $3.6M |
| Gross profit | $2.8M | $8.6M | −$3.3M | $3.3M | $494,000 | $10.8M | $10.8M | $5.4M | $2.5M | $13.0M | $184,000 | $184,000 |
| Research & development | $3.0M | $3.3M | $3.3M | $4.6M | $3.4M | $3.8M | $3.8M | $3.9M | $108.1M | $5.8M | $5.2M | $5.2M |
| Sales, general & admin | — | — | $15.1M | $9.3M | $12.6M | $16.1M | $16.1M | $12.7M | $13.0M | $14.0M | $13.1M | $10.7M |
| Total operating expenses | $12.9M | $30.6M | $26.2M | $16.2M | $16.4M | $20.1M | $27.6M | $16.9M | −$10.8M | $22.1M | $99.4M | $20.1M |
| Operating income | −$10.1M | −$22.1M | −$22.1M | −$12.9M | −$15.9M | −$9.3M | −$9.5M | −$11.5M | $13.3M | −$7.4M | −$99.3M | −$16.3M |
| Interest income | — | — | $62,000 | $62,000 | $62,000 | $76,000 | $77,000 | $77,000 | $67,000 | $110,000 | $115,000 | $23,000 |
| Interest expense | $352,000 | $897,000 | $897,000 | $1.5M | $1.9M | $1.8M | $1.8M | $1.8M | $663,000 | $1.1M | $971,000 | $971,000 |
| Income before taxes | $675,000 | −$24.4M | −$24.4M | −$23.1M | −$24.5M | −$13.3M | −$13.3M | −$16.1M | $9.6M | −$22.0M | −$93.9M | −$93.9M |
| Income taxes | — | $3,000 | — | −$3,000 | — | $13.5M | — | −$13.5M | $10,000 | — | $2.1M | — |
| Net income | $675,000 | −$24.4M | −$24.4M | −$23.1M | −$24.5M | −$13.3M | −$13.3M | −$16.1M | $9.5M | −$22.0M | −$93.9M | −$93.9M |
| EBITDA | $1.6M | −$21.7M | −$21.7M | −$19.8M | −$20.7M | −$7.6M | −$9.6M | −$12.5M | −$8.6M | — | −$90.6M | — |
| EPS (diluted) | $0.02 | $0.02 | — | −$0.88 | −$1.02 | −$0.60 | −$0.59 | −$0.73 | −$0.30 | −$1.03 | −$0.50 | −$0.50 |
| Gross margin | 72.5% | 208.5% | −79.7% | 61.8% | 8.6% | 59.5% | 59.5% | 58.2% | 20.7% | 88.8% | 4.9% | 4.9% |
| Operating margin | −263.5% | −537.5% | −537.5% | −244.1% | −276.6% | −51.2% | −52.2% | −124.0% | 109.9% | −50.2% | −2,621.7% | −430.5% |
| Net margin | 17.6% | −593.6% | −593.6% | −436.7% | −427.5% | −73.3% | −73.3% | −173.2% | 78.8% | −149.9% | −2,479.6% | −2,479.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CELU's financial statements (latest annual report filed April 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CELU financial results
In fiscal year 2025 (ended December 31, 2025), Celularity reported revenue of $26.6 million, down 51.0% from the year before. It had a net loss of $91.8 million, a net profit margin of −345.8%. Diluted earnings per share came to −$3.18. Over five years revenue grew at an average rate of 13.2% a year.
See the CELU stock overview for the latest quote and news, or the CELU chart for price history and technical indicators.
CELU income statement FAQ
What is Celularity's annual revenue?
Celularity reported total revenue of $26.6 million for fiscal year 2025, which ended on December 31, 2025. That was down 51.0% from $54.2 million the previous year.
Is Celularity profitable?
No. Celularity reported a net loss of $91.8 million in fiscal 2025, a net profit margin of −345.8%; its operating margin was −230.9%.
What is Celularity's gross margin?
Celularity's gross margin was 76.0% in fiscal 2025: for every $100 of revenue, Celularity kept $76 after the direct cost of its products and services.
How much does Celularity spend on research and development?
Celularity spent $15.0 million on research and development in fiscal 2025, 56.6% of revenue.
How fast is Celularity growing?
Revenue grew 13.2% a year on average over the last five fiscal years, from $14.3 million to $26.6 million.
What are Celularity's earnings per share?
Celularity earned $-3.18 per diluted share in fiscal 2025, compared with $-2.65 a year earlier.
When will Celularity report its next earnings?
Celularity is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Celularity's fiscal year end?
Celularity's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 30, 2026.